Core Viewpoint - The company, Lushang Freda Pharmaceutical Co., Ltd., reported a decline in revenue and profit for the first half of 2025, primarily due to challenges in the cosmetics and pharmaceutical sectors, including product iteration and pricing pressures from expanded procurement policies [1][2][3]. Company Overview and Financial Indicators - The company reported a total revenue of approximately 1.79 billion yuan for the first half of 2025, a decrease of 7.05% compared to the same period last year [2]. - The total profit for the period was approximately 153 million yuan, down 17.31% year-on-year [2]. - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was approximately 107.96 million yuan, reflecting a decrease of 15.16% [2]. - The total assets of the company at the end of the reporting period were approximately 6.04 billion yuan, showing a slight increase of 0.61% from the previous year [2]. Industry and Main Business Situation - The company operates in the cosmetics, pharmaceuticals, and raw materials sectors, with a focus on product innovation and market expansion [3][5]. - The domestic cosmetics market has shown signs of slowing growth, with retail sales growth of cosmetics lagging behind overall retail sales growth [3]. - The pharmaceutical sector is facing challenges due to expanded procurement policies and price reductions for winning products, impacting revenue generation [3][5]. Business Performance - The cosmetics segment reported a revenue of approximately 5.54 billion yuan, a year-on-year increase of 23.78%, while the brand "Aier Doctor" saw a significant revenue decline of 29.97% [10][11]. - The company has launched over 80 new products in the cosmetics sector during the reporting period, including key products from various brands [12][13]. - The pharmaceutical segment has been actively developing new products and enhancing brand visibility through participation in industry conferences and events [11][14]. Sales and Marketing Strategies - The company has established a comprehensive online and offline sales network, with online sales accounting for 84.20% of total revenue in the cosmetics segment [11]. - The marketing strategy includes leveraging social media and e-commerce platforms for brand promotion and customer engagement [10][11]. - The company is focusing on enhancing its product offerings and optimizing pricing strategies to improve market competitiveness [10][11]. Research and Development - The company has made significant advancements in research and development, particularly in the field of hyaluronic acid, which is widely used across various industries [3][8]. - The R&D efforts are supported by collaborations with academic institutions and the establishment of technology innovation systems [12][14]. - The company has received multiple certifications for its production facilities, emphasizing its commitment to quality and sustainability [15].

Core Points - The company reported a total asset of approximately 6.04 billion yuan, reflecting a slight increase of 0.61% compared to the previous year [1] - The operating revenue for the reporting period was approximately 1.79 billion yuan, showing a decrease of 7.05% year-on-year [1] - The total profit amounted to approximately 153.14 million yuan, which is a decline of 17.31% compared to the same period last year [1] - The net profit attributable to shareholders was approximately 0.11 yuan per share, down 15.38% from the previous year [1] Financial Summary - Total assets at the end of the reporting period were 6,037,060,817.19 yuan, compared to 6,000,330,923.23 yuan at the end of the previous year [1] - Operating revenue decreased from 1,925,374,405.82 yuan to 1,789,541,668.33 yuan [1] - Total profit decreased from 185,198,599.49 yuan to 153,143,384.43 yuan [1] - The net profit attributable to shareholders decreased from 0.13 yuan per share to 0.11 yuan per share [1] Shareholder Information - The largest shareholder, Shandong Commercial Group Co., Ltd., holds 51.62% of the shares, amounting to 524,739,200 shares [2] - Other significant shareholders include Shandong World Trade Center and LuShang Group Co., Ltd., holding 0.97% and 1.69% respectively [2] - The total number of shareholders at the end of the reporting period was 47,512 [1]

Core Viewpoint - The board of directors of Lushang Furuida Pharmaceutical Co., Ltd. held its sixth meeting of the twelfth session, where several key resolutions were passed regarding the company's financial report, action plans, risk assessments, and governance structure [1][2][3][4] Group 1: Financial and Operational Reports - The board unanimously approved the "2025 Semi-Annual Report" which reflects the company's financial status and operational results for the first half of 2025 [1] - The board also approved the "Semi-Annual Evaluation Report on the 'Quality Improvement and Efficiency Enhancement Return' Action Plan" [2] Group 2: Governance and Structural Changes - The board approved a proposal to cancel the supervisory board and amend the company's articles of association, allowing the audit committee to assume the supervisory functions [3] - A resolution was passed to revise and establish certain governance systems in accordance with relevant laws and regulations, reflecting the changes in the company's governance structure [4] - The board appointed Dou Qianqian as the company secretary, with her term aligned with the current board's term [2]

Core Viewpoint - The independent directors of Lushang Furuida Pharmaceutical Co., Ltd. convened a special meeting to review and approve a risk assessment report regarding Shandong Provincial Commercial Group Financial Co., Ltd., concluding that there are no significant deficiencies in its risk management [1][2]. Group 1 - The special meeting of the independent directors was held on August 19, 2025, and was legally valid as per relevant regulations [1]. - The independent directors unanimously approved the risk assessment report, which reflects the operational qualifications, internal controls, management, and risk management status of Shandong Provincial Commercial Group Financial Co., Ltd. [2]. - The report indicates that Shandong Provincial Commercial Group Financial Co., Ltd. is under strict supervision by the China Banking and Insurance Regulatory Commission, ensuring its business scope and internal risk control measures are adequately managed [2].

Group 1 - The company has decided to abolish the supervisory board and amend its articles of association and governance systems to comply with the new Company Law effective from July 1, 2024 [1][2] - The supervisory board's functions will be transferred to the audit committee of the board of directors, and relevant rules regarding the supervisory board will be abolished [1][2] - The amendments to the articles of association are based on the latest regulations from the Company Law, the Guidelines for Articles of Association of Listed Companies, and the Shanghai Stock Exchange Listing Rules [2][3] Group 2 - The company was established as a joint-stock company in 1993, with major sponsors including Wan Jie Group and several textile and chemical factories [3][4] - The company underwent a restructuring in 1998, merging with Shandong Zibo Wanjie Medical Co., Ltd., and received a new certificate of approval from the provincial government [4] - The company has undergone several regulatory confirmations and has been compliant with the Company Law since its establishment [4][5] Group 3 - The company aims to enhance its operational standards and governance in line with legal requirements and its actual circumstances [1][2] - The governance structure will be revised to ensure compliance with the latest legal frameworks and to improve the company's operational efficiency [1][2] - The company is committed to maintaining the rights and interests of its shareholders while ensuring a transparent and fair governance process [1][2]

证券代码：600223 证券简称：福瑞达 编号：临 2025-025 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 会议召开时间：2025 年 8 月 29 日（星期五）14:00-15:00 ? 网络参与地址：上证路演中心平台（http://roadshow.sseinfo.com/） ? 会议召开方式：上证路演中心网络文字互动 ? 问题征集方式：投资者可于 2025 年 8 月 22 日（星期五）至 8 月 28 日 （星期四）16:00 前将需要了解的情况和相关问题通过电子邮件的形式发送至公 司投资者关系邮箱：lsfrd600223@163.com。公司将在业绩说明会上对投资者普 遍关注的问题进行回答。 鲁商福瑞达医药股份有限公司（以下简称"公司"）于 2025 年 8 月 22 日披露 公司 2025 年半年度报告，为了便于广大投资者更全面深入地了解公司 2025 年上 半年业绩和经营情况，公司拟于 2025 年 8 月 29 日（星期五）14:0 ...

Core Viewpoint - The announcement provides key operational data for Lushang Furuida Pharmaceutical Co., Ltd. for the second quarter of 2025, highlighting production, sales, and revenue figures for its main products, particularly in the skincare category [1]. Group 1: Main Operational Data - In Q2 2025, the company produced 28,381,516 units of skincare products, sold 27,833,821 units, and generated revenue of 567,283,215.88 yuan [1]. Group 2: Price Changes - The average selling price of skincare products increased by 2.52% year-on-year and 3.03% quarter-on-quarter, with an average price of 20.38 yuan per unit in Q2 2025 [1]. - The company experienced various price fluctuations in its main raw materials, with increases and decreases across different categories, including packaging materials and active ingredients [1]. Group 3: Significant Operational Impact - There are no other significant matters affecting the company's production and operations reported in this announcement [1].

Group 1 - The core viewpoint of the report is that Shandong Provincial Commercial Group Financial Co., Ltd. has established a comprehensive internal control system and effectively manages risks, ensuring compliance with regulatory requirements [1][8] - The financial company was established with a registered capital of 2 billion RMB and has been operational since April 28, 2012, focusing on various financial services for its member units [1][2] - As of June 30, 2025, the financial company reported total assets of 843.59 million RMB, net assets of 248.34 million RMB, operating income of 11.75 million RMB, and net profit of 5.34 million RMB [6][7] Group 2 - The financial company has a governance structure that includes a board of directors, a supervisory board, and senior management, ensuring effective decision-making and oversight [2][4] - The company has implemented a risk management framework that includes regular audits and compliance checks, with no significant operational risks reported [6][8] - The company maintains a strong liquidity position, with deposits amounting to 150.47 million RMB, representing 51.05% of its cash balance, and a borrowing balance of 1.5 million RMB, accounting for 6.52% of total financing [7][8]

Group 1 - The company appointed Ms. Dou Qianqian as the secretary of the board of directors during the sixth meeting of the twelfth board on August 20, 2025 [1] - Ms. Dou has completed the necessary training and holds the required qualifications to perform the duties of the board secretary, as confirmed by the Shanghai Stock Exchange [1][2] - The term of Ms. Dou as board secretary will align with the current twelfth board of directors [1] Group 2 - Ms. Dou Qianqian, born in November 1982, has a master's degree and is a deputy chief pharmacist with extensive experience in the pharmaceutical industry [2] - She has held various positions within the Shandong Furuida Pharmaceutical Group, including deputy director of the Technology Development Department and assistant general manager [2] - Ms. Dou holds 14,300 shares of the company and has no conflicts of interest with major shareholders or other executives [2]

第三条 公司董事离职管理应遵循以下原则： （一）合法合规原则：严格遵守国家法律法规、监管规定及公司章程的要求； 第一章 总 则 第一条 为规范鲁商福瑞达医药股份有限公司（以下简称"公司"）董事离职 程 序，确保公司治理结构的稳定性和连续性，维护公司及股东的合法权益，公司根 据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证 券法》（以下简称"《证券法》"）、《上市公司治理准则》《上海证券交易所股 票上市规则》《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》 等法律法规、规范性文件、证券交易所业务规则及《鲁商福瑞达医药股份有限公司 章程》（以下简称"公司章程"）的有关规定，结合公司实际情况，制定本制度。 第二条 本制度适用于全体董事，包括非独立董事、独立董事以及职工董事离 职的情形。 （二）公开透明原则：及时、准确、完整地披露董事离职相关信息； （三）平稳过渡原则：确保董事离职不影响公司正常经营和治理结构的稳定性； （四）保护股东权益原则：维护公司及全体股东的合法权益。 第二章 离职情形与程序 第四条 公司董事离职包含任期届满未连任、主动辞职、被解除职务以及其他 导致董事实际离 ...